Focused ultrasound enhances CRISPR delivery to the...
CMN Briefs
Feb. 4, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Refuge Biotechnologies
Main focus: CAR-T cells for cancer treatment
Company stage: Clinical
Diseases: Breast cancer, head and neck cancer, liver cancer, diffuse large B-cell lymphoma (DLBCL)
Genome editing tool: CRISPR-Cas9/dCas9
Funding stage: Private
Location: Menlo Park, CA, USA
Website: https://refugebiotech.com/
Pipeline: https://refugebiotech.com/#programs
Partnerships: 3SBio
Refuge Biotech is a pre-clinical stage cancer immunotherapy company. The company uses a modified dCas9-based platform to engineer its CAR-T cell therapies, mainly for the treatment of solid tumours. Its dCas9 system is used in two ways: CRISPRa (activation) and CRISPRi (interference), which lead to either transcriptional activators or repression of target genes.
